28 October 2015 - The CADTH Canadian Drug Expert Committee has recommended that secukinumab be listed for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, so long as treatment is discontinued if a PASI 75 response has not been demonstrated after 12 weeks.

For more details, go to: https://www.cadth.ca/sites/default/files/cdr/complete/SR0407_Cosentyx_Oct-30-15.pdf